Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications.

As the end organ for the treatment of local diseases or as the route of administration for systemic therapies, the lung is a very attractive target for drug delivery. It provides direct access to disease in the treatment of respiratory diseases, while providing an enormous surface area and a relatively low enzymatic, controlled environment for systemic absorption of medications. As a major port of entry, the lung has evolved to prevent the invasion of unwanted airborne particles from entering into the body. Airway geometry, humidity, mucociliary clearance and alveolar macrophages play a vital role in maintaining the sterility of the lung and consequently are barriers to the therapeutic effectiveness of inhaled medications. In addition, a drug's efficacy may be affected by where in the respiratory tract it is deposited, its delivered dose and the disease it may be trying to treat.

[1]  R. Wolff,et al.  Safety of inhaled proteins for therapeutic use. , 1998, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[2]  V. Roggli,et al.  Immunohistologic quantification of Pseudomonas aeruginosa in the tracheobronchial tree from patients with cystic fibrosis. , 1995, Pediatric pathology & laboratory medicine : journal of the Society for Pediatric Pathology, affiliated with the International Paediatric Pathology Association.

[3]  G. K. Adams,et al.  Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. , 1993, JAMA.

[4]  J. Mauderly,et al.  Deposition and Clearance of Radiolabeled Particles from Small Ciliated Airways in Beagle Dogs , 1989 .

[5]  M. Decramer,et al.  Regulation of mucociliary clearance in health and disease. , 1999, The European respiratory journal.

[6]  P. Bye,et al.  Mucociliary clearance in cystic fibrosis , 2002, Pediatric pulmonology.

[7]  J. Lewis,et al.  Respiratory tract uptake of inhalants and metabolism of xenobiotics. , 1993, Annual review of pharmacology and toxicology.

[8]  A. Ryrfeldt The Bronchial Circulation—A Significant Local Distribution System in the Lung, in Inhalation Therapy? , 1990 .

[9]  J. Patton,et al.  Drug delivery via the respiratory tract. , 1994, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[10]  C. Garrard,et al.  Theoretic analysis of sites of aerosol deposition in the human lung. , 1981, Chest.

[11]  M. Newhouse,et al.  Aerosol penetration into the lung; influence on airway responses. , 1981, Chest.

[12]  T. Isawa,et al.  Mucociliary clearance and transport in bronchiectasis: global and regional assessment. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  A. Yamamoto,et al.  Absorption Enhancement of Intrapulmonary Administered Insulin by Various Absorption Enhancers and Protease Inhibitors in Rats , 1994, The Journal of pharmacy and pharmacology.

[14]  R. Perry,et al.  Interpretation of "24 Hour Lung Retention" in Studies of Mucociliary Clearance , 1988 .

[15]  U. Klotz,et al.  Extrahepatic Metabolism of Drugs in Humans , 1994, Clinical pharmacokinetics.

[16]  M. Newhouse,et al.  Effect of chest physiotherapy on the removal of mucus in patients with cystic fibrosis. , 2015, The American review of respiratory disease.

[17]  J. Crapo,et al.  Allometric relationships of cell numbers and size in the mammalian lung. , 1992, American journal of respiratory cell and molecular biology.

[18]  C. P. Yu,et al.  Theoretical Lung Deposition of Hygroscopic NaCl Aerosols , 1985 .

[19]  S. Clarke,et al.  Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Efficacy and pulmonary deposition. , 1989, Chest.

[20]  J. Forrest,et al.  Nasal ciliary ultrastructure and function in patients with primary ciliary dyskinesia compared with that in normal subjects and in subjects with various respiratory diseases. , 1984, The American review of respiratory disease.

[21]  J. Lammers,et al.  Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. , 1996, Thorax.

[22]  Q A Summers,et al.  Inhaled drugs and the lung , 1991, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[23]  S. Anderson,et al.  Regional deposition of saline aerosols of different tonicities in normal and asthmatic subjects. , 1994, The European respiratory journal.

[24]  M. Newhouse,et al.  The effects of preferential deposition of histamine in the human airway. , 2015, The American review of respiratory disease.

[25]  W. Kreyling,et al.  Comparison of experimental and calculated data for the total and regional deposition in the human lung , 1985 .

[26]  T. Clark,et al.  The importance of particle size in response to inhaled bronchodilators. , 1982, European journal of respiratory diseases. Supplement.

[27]  B. Karlberg,et al.  Intrapulmonary administration of insulin to healthy volunteers , 1996, Journal of internal medicine.

[28]  R. Loddenkemper,et al.  Patterns of distribution and clearance of aerosols in patients with bronchiectasis. , 2015, The American review of respiratory disease.

[29]  J. Ilowite,et al.  Regional deposition of aerosolized pentamidine. Effects of body position and breathing pattern. , 1990, Annals of internal medicine.

[30]  H. Wagner,et al.  The effect of bronchial obstruction on central airway deposition of a saline aerosol in patients with asthma. , 1986, The American review of respiratory disease.

[31]  P. Barnes,et al.  Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. , 1990, The American review of respiratory disease.

[32]  A. James,et al.  The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. , 1997, The European respiratory journal.

[33]  M. Dolovich New propellant-free technologies under investigation. , 1999, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[34]  J. Markham,et al.  Pulmonary deposition of aerosols in children with cystic fibrosis. , 1974, The Journal of pediatrics.

[35]  H S Shannon,et al.  Effect of lung function and mode of inhalation on penetration of aerosol into the human lung. , 1977, Thorax.

[36]  L. Heinemann,et al.  Time–action Profile of Inhaled Insulin , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[37]  S. Newman,et al.  Aerosol deposition considerations in inhalation therapy. , 1985, Chest.

[38]  Günter Oberdörster,et al.  Estimation of the Deposition of Aerosolized Drugs in the Human Respiratory Tract Due to Hygroscopic Growth , 1989 .

[39]  B. Karlberg,et al.  Effects of intrapulmonary insulin in patients with non-insulin-dependent diabetes. , 1996, Scandinavian journal of clinical and laboratory investigation.

[40]  M. Newhouse,et al.  Aerosol penetrance: a sensitive index of peripheral airways obstruction. , 1976, Journal of applied physiology.

[41]  Effros Rm,et al.  Measurements of pulmonary epithelial permeability in vivo. , 1983, The American review of respiratory disease.

[42]  R. V. Lourenço,et al.  Clinical aerosols. I. Characterization of aerosols and their diagnostic uses. , 1982, Archives of internal medicine.

[43]  R. Upton,et al.  KINETIC ASPECTS OF DRUG DISPOSITION IN THE LUNGS , 1999, Clinical and experimental pharmacology & physiology.

[44]  A. Sant'annaGandra Aerosols in medicine , 1957 .

[45]  M. Hashida,et al.  Improvement of the Pulmonary Absorption of (Asu1,7)-Eel Calcitonin by Various Protease Inhibitors in Rats , 1994, Pharmaceutical Research.

[46]  T. Martonen Mathematical model for the selective deposition of inhaled pharmaceuticals. , 1993, Journal of pharmaceutical sciences.

[47]  G. Smaldone,et al.  Quantitative deposition of aerosolized gentamicin in cystic fibrosis. , 1987, The American review of respiratory disease.

[48]  R. Baltimore,et al.  Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration. , 1989, The American review of respiratory disease.

[49]  M. Matthay,et al.  Clearance of different-sized proteins from the alveolar space in humans and rabbits. , 1992, Journal of applied physiology.

[50]  Pieter Zanen,et al.  The optimal particle size for β-adrenergic aerosols in mild asthmatics , 1994 .

[51]  H. Folkesson,et al.  Permeability of the respiratory tract to different-sized macromolecules after intratracheal instillation in young and adult rats. , 1990, Acta physiologica Scandinavica.

[52]  A. Dobs,et al.  Time to peak insulin level, relative bioavailability, and effect of site of deposition of nebulized insulin in patients with noninsulin-dependent diabetes mellitus. , 1998, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[53]  J. Heyder,et al.  Effect of cystic fibrosis on inhaled aerosol boluses. , 1989, The American review of respiratory disease.

[54]  R. Djukanović,et al.  Alveolar tissue inflammation in asthma. , 1996, American journal of respiratory and critical care medicine.

[55]  H. Folkesson,et al.  Alveolar epithelial clearance of protein. , 1996, Journal of applied physiology.

[56]  A. Morice,et al.  Pulmonary clearance of vasoactive intestinal peptide. , 1986, Thorax.

[57]  J. Heyder Particle transport onto human airway surfaces. , 1982, European journal of respiratory diseases. Supplement.

[58]  P. Barnes,et al.  Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. , 1985, The American review of respiratory disease.

[59]  J. Patton,et al.  Mechanisms of macromolecule absorption by the lungs , 1996 .

[60]  R. Schleimer Uptake, Retention, and Biotransformation of Corticosteroids in the Lung and Airways , 2001 .